Johnson & Johnson (NYSE: JNJ) today announced new data from the late-breaking VARIPURE and Omny-IRE studies presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 Annual Meeting in Busan, South Korea. Both studies were published simultaneously in Europace and Heart Rhythm, respectively.

• Effectiveness and safety results: enrolled patients had 100% acute procedural success. Study data also shows one primary adverse event (0.4%) that was resolved without sequelae, and zero reported stroke, coronary spasm, acute kidney injury, or death.i
• Workflow evaluation: Mean ablation duration of 17.9 minutes, and single-catheter mapping and ablation used in 88.9% of cases.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.